What Conditions Does PRP Treat: The Complete Body-Region Guide for 2026 Patients

Introduction: Why PRP Treats Far More Than You Think

Consider a patient who has just been told they need knee replacement surgery. Before scheduling the operation, they discover that Platelet-Rich Plasma therapy might offer an alternative. This scenario plays out thousands of times each year as patients learn about the expanding applications of this regenerative treatment.

PRP, or Platelet-Rich Plasma, is an autologous concentrate derived from a patient’s own blood. This concentrate releases powerful growth factors including VEGF, PDGF, and TGF-β that orchestrate tissue repair, immunomodulation, and angiogenesis throughout the body. The result is a versatile therapeutic tool with applications far beyond what most patients realize.

The scope problem is significant. Most online resources cover only three or four conditions: knee osteoarthritis, tennis elbow, hair loss, and skin rejuvenation. This limited coverage leaves patients unaware of fifteen or more additional treatable conditions spanning multiple body systems and medical specialties.

This comprehensive guide organizes PRP applications by body region and specialty, allowing readers to navigate directly to their relevant anatomy. Each condition includes an evidence tier classification, realistic timelines, and outcome data to help patients make informed decisions. At Unicorn Bioscience, the emphasis on platelet concentration exceeding 1,000,000/µL serves as a quality threshold that significantly influences treatment outcomes.

How to Use This Guide: Understanding the Evidence Tiers

This article employs a three-tier evidence classification system to help readers calibrate their expectations for each condition.

Level I (RCT-Proven): Conditions supported by multiple randomized controlled trials and meta-analyses. These represent the strongest clinical consensus. Examples include knee osteoarthritis, tennis elbow, androgenetic alopecia, and plantar fasciitis.

Level II (Strong Clinical Evidence): Conditions supported by well-designed cohort studies, systematic reviews of observational data, or smaller RCTs with consistent findings. Examples include frozen shoulder, diabetic foot ulcers, and erectile dysfunction.

Emerging (Promising Early Evidence): Conditions with compelling pilot data, case series, or early-phase trials but lacking large-scale RCT confirmation. Examples include anosmia, ovarian rejuvenation, and uterine scar repair. “Emerging” does not mean “unproven”; it means the science is actively developing with encouraging early results.

As of 2026, the FDA has not approved PRP for most specific indications. PRP is classified as an autologous biologic, not a drug, and all treatments at Unicorn Bioscience are administered within FDA regulatory frameworks. Individual candidacy depends on factors beyond diagnosis: age, inflammation levels, injury severity, medications, and health goals.

Lower Extremity Conditions: Knee, Ankle, and Foot

The lower extremity represents the most evidence-rich body region for PRP, where the strongest Level I data exists. These conditions account for a significant share of orthopedic PRP applications globally.

Knee Osteoarthritis (KOA)

Evidence Tier: Level I

A 2025 meta-analysis encompassing 18 RCTs and 1,995 patients demonstrated that PRP exceeded the Minimal Clinically Important Difference (MCID) for pain and function at every timepoint through 12 months. PRP outperforms hyaluronic acid and corticosteroids, especially in mild-to-moderate KOA (Kellgren-Lawrence grades I through III).

Results prove meaningful only when platelet concentration exceeds 1,000,000 platelets/µL for consistent clinical benefit. Research published in Frontiers in Physiology shows PRP combined with hyaluronic acid is superior to PRP monotherapy. Patients typically notice improvement at 4 to 8 weeks, with peak benefit at 3 to 6 months and effects lasting 12 months or longer.

Over 600,000 knee replacements are performed annually in the United States, yet studies suggest up to 80% of patients told they need total knee replacement may not actually require surgery. Patients exploring this option may benefit from reviewing knee replacement alternatives before making a final decision.

Plantar Fasciitis

Evidence Tier: Level I

Plantar fasciitis ranks among the highest success-rate conditions for PRP. The treatment outperforms corticosteroid injections for long-term outcomes; while steroids provide faster short-term relief, PRP delivers more durable results through collagen remodeling and neovascularization in the degenerated plantar fascia.

Patients experience initial relief at 4 to 6 weeks with full benefit at 3 to 6 months. Ideal candidates include patients with chronic plantar fasciitis exceeding 3 months who have failed conservative care including stretching, orthotics, and NSAIDs.

Achilles Tendinitis and Tendinopathy

Evidence Tier: Level I

A November 2025 meta-analysis of 36 RCTs involving approximately 2,000 patients demonstrated significant pain reduction at 6 weeks, 3 months, 6 months, and 12 months for tendon conditions. Both insertional and mid-portion Achilles tendinopathy respond to PRP, which promotes intrinsic tendon healing by stimulating tenocyte proliferation and collagen synthesis.

Patellar Tendinopathy (Jumper’s Knee)

Evidence Tier: Level I

Common in basketball, volleyball, and running athletes, this condition involves degenerative tendon changes that resist conventional treatment. The same meta-analysis evidence base supports patellar tendinopathy treatment, with patients experiencing initial improvement at 4 to 8 weeks and return to sport at 3 to 6 months.

Ankle Ligament Sprains and Instability

Evidence Tier: Level II

PRP accelerates ligament healing in acute and chronic ankle ligament sprains by stimulating fibroblast activity and collagen remodeling. This application proves particularly useful for athletes needing faster return to play and patients with chronic ankle instability who want to avoid surgical stabilization.

Upper Extremity Conditions: Shoulder, Elbow, Wrist, and Hand

Upper extremity conditions represent a large share of PRP orthopedic applications, particularly in working-age adults and athletes.

Lateral Epicondylitis (Tennis Elbow)

Evidence Tier: Level I

One of the most studied PRP applications, tennis elbow treatment consistently outperforms corticosteroid injections for long-term outcomes in multiple high-quality RCTs. PRP reverses the degenerative tendinosis at the common extensor origin, stimulating true tissue healing rather than temporary inflammation suppression.

The 36-RCT meta-analysis shows sustained pain reduction at 6 weeks, 3, 6, and 12 months. While corticosteroids may feel faster initially, PRP provides superior 6 to 12 month outcomes. This evidence also applies to medial epicondylitis (golfer’s elbow). Patients can learn more about elbow pain regenerative treatment options to understand the full range of available approaches.

Rotator Cuff Tendinopathy and Partial Tears

Evidence Tier: Level I

Research reveals rotator cuff retear rates of 16.5% with PRP versus 23.6% without (P=0.002). PRP serves both as a standalone treatment for tendinopathy and as a surgical adjunct to improve post-repair healing, addressing supraspinatus, infraspinatus, and subscapularis tendinopathy. For patients seeking to avoid surgery, non-surgical rotator cuff tear treatment offers a detailed overview of conservative options.

Frozen Shoulder (Adhesive Capsulitis)

Evidence Tier: Level I

A systematic review of 14 RCTs involving 1,024 patients found PRP more durable and safer than corticosteroids for frozen shoulder. PRP addresses the fibrotic capsular changes underlying adhesive capsulitis rather than inflammation alone, with meaningful range-of-motion improvement at 4 to 8 weeks and full benefit at 3 to 6 months.

Carpal Tunnel Syndrome

Evidence Tier: Level I

PRP injected around the median nerve reduces perineural fibrosis, decreases nerve compression, and promotes nerve regeneration. This offers a non-surgical alternative to carpal tunnel release surgery for mild-to-moderate cases, with symptom improvement at 4 to 8 weeks. Patients with related wrist concerns may also want to explore wrist injury regenerative treatment options.

Hip and Pelvis Conditions

The hip represents a growing application area for PRP, particularly relevant for older adults with hip osteoarthritis and active patients with labral and tendon injuries.

Hip Osteoarthritis

Evidence Tier: Level II

Similar mechanisms to knee osteoarthritis apply; PRP reduces synovial inflammation and promotes cartilage matrix preservation. While the evidence base is smaller than for knee osteoarthritis, results are consistently positive in cohort studies and smaller RCTs. PRP offers an alternative to corticosteroid injections and may delay or prevent hip replacement.

Greater Trochanteric Bursitis and Gluteal Tendinopathy

Evidence Tier: Level I

PRP outperforms corticosteroid injections for long-term outcomes in trochanteric bursitis and gluteal tendinopathy. Patients experience pain reduction at 4 to 8 weeks with full functional improvement at 3 to 6 months.

Spine and Neck Conditions

Spine applications represent a rapidly developing area for PRP, with uses ranging from facet joint injections to disc herniation treatment.

Facet Joint Arthritis and Sacroiliac Joint Dysfunction

Evidence Tier: Level II

PRP injected into facet joints or the sacroiliac joint reduces inflammatory pain and promotes joint stabilization. This proves particularly useful for patients with chronic low back or neck pain from facet arthropathy who have had only temporary relief from corticosteroid injections.

Intervertebral Disc Herniation and Degenerative Disc Disease

Evidence Tier: Emerging

Intradiscal PRP injections aim to restore disc matrix integrity and reduce inflammatory cytokines within the disc. Early clinical studies show promising results for pain reduction and functional improvement, though larger RCTs remain ongoing.

Muscle Injuries: Strains, Tears, and Recovery

Evidence Tier: Level I

PRP accelerates muscle fiber regeneration, reduces scar tissue formation, and shortens return-to-play timelines for athletes. Applications include hamstring strains, quadriceps tears, calf muscle injuries, and adductor strains. PRP can accelerate muscle healing by 25 to 40% compared to standard care, with typical return to sport 2 to 4 weeks earlier.

Hair Restoration: Androgenetic Alopecia and Beyond

Hair restoration represents one of the most evidence-rich non-orthopedic applications for PRP, with approximately 80 million U.S. adults affected by androgenetic alopecia.

Male and Female Pattern Baldness

Evidence Tier: Level I

A 2025 systematic review and meta-analysis encompassing 43 RCTs and 1,877 participants confirmed that activated PRP significantly increases hair density and reduces recurrence versus placebo. Success rates reach 70 to 80% in early-to-moderate androgenetic alopecia, with 93% of male pattern baldness patients in one cohort reporting complete cessation of hair loss within 2 months.

PRP growth factors stimulate dormant hair follicles, extend the anagen (growth) phase, and increase follicular vascularity. Initial results become visible at 3 to 4 months with full results at 6 to 12 months.

PRP as an Adjunct to Hair Transplantation

Evidence Tier: Level I

A 2025 systematic review found PRP alongside hair transplantation is associated with increased hair density, enhanced follicle survival, and earlier initiation of hair growth. Unicorn Bioscience’s advisory board includes Dr. Roy Stoller, a founding member of the International Society of Hair Restoration Surgery, and Dr. Glenn M. Charles, a past president of the International Society of Hair Restoration Surgery, lending specific expertise in this application.

Wound Healing: Chronic and Diabetic Wounds

Wound healing represents a clinically significant but underreported application area for PRP. Diabetic and ischemic wounds lack the growth factors needed for healing; PRP delivers a concentrated dose directly to the wound bed.

Diabetic Foot Ulcers

Evidence Tier: Level II (Approaching Level I)

A 2025 RCT found 87.5% of PRP-treated patients achieved complete ulcer healing by 12 weeks versus significantly lower rates with standard care. PRP addresses the growth factor deficiency in diabetic wounds, stimulating angiogenesis, epithelialization, and granulation tissue formation.

Sexual Wellness: Erectile Dysfunction and Female Sexual Dysfunction

Erectile dysfunction affects tens of millions of men, and over 40% of U.S. women experience some form of sexual dysfunction, representing a significant patient population.

Erectile Dysfunction

Evidence Tier: Level II

A landmark clinical study found 69% of men receiving PRP achieved clinically meaningful improvement at 6 months versus 27% in the placebo group. PRP restores penile nerve function, improves arterial blood flow, and promotes smooth muscle regeneration. Initial improvement occurs at 4 to 8 weeks with full benefit at 3 to 6 months.

Female Sexual Dysfunction

Evidence Tier: Level II

PRP injected into clitoral and anterior vaginal wall tissues restores sensitivity, improves blood flow, and rejuvenates collagen in the vaginal mucosa. Studies show high rates of improvement in desire, arousal, lubrication, orgasm quality, and overall sexual satisfaction.

Fertility and Reproductive Medicine

Ovarian Rejuvenation for Diminished Ovarian Reserve

Evidence Tier: Emerging (Approaching Level II)

A 2024 systematic review and meta-analysis encompassing 38 studies and 2,256 women found PRP treatment significantly raised AMH levels and lowered FSH in women with diminished ovarian reserve, with improved IVF outcomes. This application is indicated for women with low ovarian reserve, premature ovarian insufficiency, failed IVF cycles, and early menopause.

Anosmia: Restoring Smell After Injury or COVID-19

Evidence Tier: Emerging

A 2025 study found 67% of participants with head-injury-related anosmia improved after PRP injections. A 2023 study found COVID-19 smell loss patients were 12.5 times more likely to improve with PRP versus placebo. PRP growth factors promote olfactory nerve regeneration and reduce neuroinflammation in the olfactory epithelium.

PRP Safety Profile: What Patients Need to Know

PRP demonstrates an exceptional safety profile with serious complication rates below 0.1% and infection risk below 1%. Because PRP is autologous (derived from the patient’s own blood), there is no risk of allergic reaction. Adverse events are typically mild and temporary, consisting of minor bruising and soreness at the injection site that resolves within 4 to 6 days.

This contrasts favorably with corticosteroids, which carry risks of tendon weakening, cartilage damage with repeated use, and systemic effects. Surgery involves infection risk, anesthesia complications, and extended recovery periods.

What Determines PRP Success: The Key Variables

Platelet Concentration: Must exceed 1,000,000 platelets/µL for consistent clinical benefit. Low-platelet PRP consistently underperforms across all conditions.

Condition Severity: PRP works best for mild-to-moderate conditions. Severe end-stage disease has lower response rates.

Injection Accuracy: Ultrasound or fluoroscopic guidance ensures delivery to the precise target tissue. Unicorn Bioscience uses advanced imaging guidance for all injections.

Patient Factors: Age, overall health, inflammation levels, medications, and adherence to post-treatment protocols all influence outcomes.

Overall, PRP achieves clinically meaningful improvement in 50 to 70% of appropriately selected patients.

Am I a Candidate for PRP? How to Self-Assess

Strong candidate indicators include chronic conditions exceeding 3 months that have not fully responded to conservative care, mild-to-moderate severity, desire to avoid or delay surgery, and absence of contraindications such as active infection, blood disorders, or anticoagulant therapy.

A personalized consultation is the only way to determine candidacy with certainty. Unicorn Bioscience’s assessment considers inflammation levels, patient age, injury type and location, current medications, and personal health goals. Patients can also review what to expect during the treatment process to prepare for their first visit.

Conclusion: PRP’s Expanding Role in Modern Medicine

PRP’s applications span orthopedics, sports medicine, hair restoration, aesthetics, wound healing, sexual wellness, fertility, anosmia, and dentistry. The treatment has Level I RCT-proven efficacy for more than a dozen conditions, with an expanding frontier of emerging applications.

Not every patient is a candidate, and not every application carries the same evidence strength. Quality of PRP preparation and delivery matters enormously. The global PRP market is growing at 11 to 13% annually, driven by accumulating evidence and growing patient demand for non-surgical alternatives.

Patients deserve to know all their options before accepting surgery or living with chronic pain. This guide serves as a starting point; a consultation represents the next step. Those interested in understanding the full scope of platelet-rich plasma therapy can explore a detailed overview of how the treatment works.

Take the Next Step: Find Out If PRP Is Right for Your Condition

Patients interested in exploring PRP therapy can book a free consultation, either virtual or in-person, with Unicorn Bioscience to discuss their specific condition and candidacy. Same-day treatment is available for qualified candidates.

Unicorn Bioscience operates eight locations: Austin, Dallas, El Paso, Fort Worth, Houston, San Antonio, Boca Raton, and Manhattan. Virtual consultations are available nationwide. Contact the team at (737) 347-0446.

The clinical transparency demonstrated throughout this article, including evidence tiers, realistic timelines, and honest success rates, reflects Unicorn Bioscience’s patient-first approach. The team provides honest assessments of whether PRP is appropriate for each condition, including when it may not be the best option, so patients can make informed decisions about their health.